Novo Nordisk is aware of 10 deaths from compounded weight-loss drug copies
Novo Nordisk said on Wednesday it is aware of 10 deaths and 100 hospitalizations resulting from people taking compounded ...
Novo Nordisk aware of reports 10 people taking compounded weight-loss drug copies died
Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...
Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns
“Patients who believe that they’re getting access to a safe product, and they believe they’re getting ... Meanwhile, ...
Business Insider1d
Bank of America Securities Sticks to Its Buy Rating for Novo Nordisk (NVO)
Novo Nordisk (NVO) Company Description: Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two ...
Becker's Hospital Review6d
Compounded Ozempic tied to deaths, hospitalizations: Novo Nordisk CEO
Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked ...
Novo Nordisk’s Wegovy Sales Increase Reassures Investors
Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...
Novo Nordisk, in a mixed-bag earnings report, beat expectations on Wegovy sales but tightened its 2024 outlook
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...
Pharmabiz7d
Ascendis Pharma, Novo Nordisk ink collaboration to develop & commercialize TransCon technology-based products in metabolic and cardiovascular diseases
manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. The ...